AdaptHealth (AHCO) Q2 Revenue Falls 1%

AdaptHealth (AHCO) reported Q2 2025 results below analyst estimates, with GAAP revenue declining 0.7% year-over-year to $800.4 million and adjusted EBITDA margin falling to 19.4%. The company attributed the performance to sluggish organic growth and the divestiture of certain non-core assets, which also led to a reduced full-year adjusted EBITDA guidance for FY2025. Despite these operational headwinds, AHCO made progress on debt reduction and operational efficiency, with management focused on core offerings and anticipating a recovery in key segments.

Analysis

AdaptHealth (AHCO) reported a challenging second quarter for 2025, with key financial metrics falling short of both prior-year results and analyst expectations. GAAP revenue declined 0.7% year-over-year to $800.4 million, missing the consensus estimate by 0.4%, while GAAP EPS of $0.10 represented a 23.1% drop from Q2 2024. Profitability also eroded, with the adjusted EBITDA margin contracting by 1.1 percentage points to 19.4% and free cash flow for the first half of the year declining 5.9% due to increased capital expenditures. This performance reflects a combination of strategic restructuring and operational headwinds, including sluggish organic growth and market share pressure in the Sleep Health segment. A key event was the divestiture of non-core assets, which yielded a $32.2 million pre-tax gain but was also the stated reason for a reduction in full-year adjusted EBITDA guidance to a range of $642 million to $682 million. Despite these top-line pressures, the company is executing on its strategic priorities, evidenced by a $170 million reduction in long-term debt since year-end 2024 and management's commentary on sequential improvements in its Diabetes Health segment. The updated full-year guidance, which includes a slightly raised revenue floor and stable free cash flow expectations, suggests that while the company is in a transitional phase, management believes the underlying core business is stabilizing.

Key Decisions for Investors

• Investors should scrutinize upcoming quarterly results for tangible evidence of a turnaround in the core Sleep and Diabetes Health segments, as current operational headwinds are the primary risk to the investment thesis.
• The reduction in FY2025 adjusted EBITDA guidance should be viewed primarily as a consequence of strategic asset sales rather than a deterioration of the core business, making the stable free cash flow guidance a more critical metric to monitor.
• Given the ongoing debt reduction and strategic repositioning, investors may consider the stock a restructuring play, but should condition any bullish stance on management's ability to convert operational initiatives into measurable organic growth and margin expansion.